Published online before print October 6, 2005, doi: 10.1161/01.ATV.0000189157.88630.d1
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Chlamydia pneumoniae Burden in Carotid Arteries Is Associated With Upregulation of Plaque Interleukin-6 and Elevated C-Reactive Protein in Serum
From the Department of Neurology (S.C.J., M.T.L.), Division of Vascular Surgery, Department of Surgery (L.M.M.), and Department of Medicine (D.D.), University of California, San Francisco; and Children’s Hospital Oakland Research Institute (H.Z., D.D.), California.
Correspondence to Deborah Dean, MD, MPH, Children’s Hospital Oakland Research Institute, 5700 Martin Luther King Jr Way, Oakland, CA 94960. E-mail ddean{at}chori.org
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Chlamydia pneumoniae (Cpn) infection of vascular smooth muscle cells increases interleukin-6 (IL-6) secretion in vitro. In vivo, IL-6 stimulates liver C-reactive protein (CRP) production. Because serum levels of IL-6 and CRP are independent risk factors for stroke and myocardial infarction (MI), we investigated whether Cpn burden in carotid plaques might provide a link between plaque IL-6 expression and elevated serum levels of IL-6 and CRP.
Methods and Results— Consecutive patients undergoing elective carotid endarterectomy were studied. Serum levels of CRP and IL-6 were measured before surgery. Immunohistochemistry and real-time quantitative (k)RT-PCR were used to detect Cpn and the expression of IL-6 within carotid plaques. Cpn mRNA was present in 19 (37%) of 51 patients, suggesting viable infections. These patients had evidence for infection by PCR and immunohistochemistry. The Cpn burden, measured by real-time quantitative (k)-PCR using the number of organisms normalized against the number of eukaryotic cells in the tissue, was associated with plaque expression of IL-6 (Spearman R=0.55; P<0.0001), which was associated with serum levels of IL-6 (R=0.56; P<0.0001) and CRP (R=0.80; P<0.0001).
Conclusions— IL-6 secretion in atherosclerotic plaques infected with Cpn could explain elevated serum inflammatory markers in individuals at risk for stroke and MI.
Serum interleukin-6 (IL-6) and C-reactive protein (CRP) are risk factors for stroke. Carotid plaque Chlamydia pneumoniae (Cpn) burden may contribute to these factors. Burden was significantly associated with IL-6 plaque expression, which was associated with serum IL-6 and CRP. Cpn is associated with inflammation and atherogenesis via upregulation of local and systemic inflammatory markers.
Key Words: inflammatory markers • carotid atherosclerosis • IL-6 • Chlamydia pneumoniae • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Inflammation is an important component of atherosclerosis and likely contributes to atherogenesis and plaque rupture in coronary, cerebral, and peripheral vascular disease.1 Systemic markers of inflammation, such as the acute-phase reactant CRP,2 are associated with risk of myocardial infarction (MI) and stroke,3 and with poor outcomes in patients with symptomatic atherosclerosis.4 Elevated serum levels of CRP could indicate the degree of localized inflammation in plaques or a more systemic inflammation that triggers thrombosis or plaque rupture. Increasing baseline levels of the proinflammatory cytokine IL-6 also predict future cardiovascular events.5,6 Among patients presenting with acute coronary syndromes, an elevated serum level of IL-6 is a strong independent predictor of increased mortality and may be helpful in directing subsequent care.7 IL-6 is the primary determinant of CRP release from the liver and the only substance known to induce synthesis of all acute-phase proteins.8
Cpn has been found in 16% to 71% of plaques in coronary, carotid, and femoral arteries.9,10 Two recent clinical trials showed there was no observed reduction in cardiovascular events during intermittent treatment with gatifloxacin,11,12 a drug known to be effective against Cpn. However, this infectious pathogen may set in motion an inflammatory process that contributes to plaque inflammation and vascular disease progression. Yet, it remains unknown whether Cpn causes atherosclerosis or is simply an innocent bystander.
In a previous study of patients undergoing elective endarterectomy, we found that serum CRP levels were significantly elevated among those whose carotid arteries were infected with viable Cpn compared with those without infection.9 However, there are no studies that have quantitatively examined the association between plaque infection and proinflammatory cytokines. We examined this association by measuring serum levels of IL-6 and CRP, and quantifying IL-6 expression in Cpn negative and positive carotid plaques using immunohistochemistry (IHC) and real-time quantitative (k)RT-PCR.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population and Carotid Specimens
The target population consisted of patients scheduled for elective carotid endarterectomy who consented to the study and underwent nonurgent carotid endarterectomy at the University of California, San Francisco, had a preoperative clinic evaluation, and had surgical specimens available, as described in detail previously.9 The protocol was approved by the University of California, San Francisco Institutional Review Board.
The carotid artery plaque was obtained at the time of surgery, and handled sterilely.9 These plaques had a high grade of atherosclerosis. Plaques were sectioned, placed in OCT, and snap-frozen in liquid nitrogen for IHC. An adjacent carotid plaque section was used for DNA and RNA extraction for detection of Cpn and for IL-6 quantitation. Plaque sections were stored at –80°C until processed. All experiments were performed in a blinded fashion.
Immunohistochemistry
Tissue was cross-sectioned at 6 µm. For IL-6, adjacent 6-µm sections were placed on Superfrost-Plus slides (Fisher Scientific). Each slide included positive controls prepared identically to carotid sections and included a section of human tonsil and a carotid sample positive for IL-6 by monoclonal antibody (MAb) staining (see below). Negative controls were sections of tonsil reacted with secondary IgG antibody with chromogen and a carotid sample known to be negative for IL-6. Duplicates were made for all sections.
IL-6 was detected using IL-6–specific MAb (Biosource) with alkaline phosphatase–conjugated secondary antibody and Fast Red as the chromogen (Biocare). Nuclei were stained using hematoxylin. Staining was assessed under light microscopy at 40x and 100x oil using a Nikon EclipseTE200 with charge-coupled device–SpotII camera and a fixed measurement grid. Nuclei were counted to normalize the staining for IL-6 against cell number in 20 nonoverlapping fields of the same section. Results were averaged across duplicate slides.
To localize IL-6 in relation to Cpn, an IL-6–stained section was probed with a chlamydial-specific heat shock protein 60 (CHsp60) MAb (Affinity Bioreagents), and a duplicate slide was probed with a chlamydial lipopolysaccharide genus-specific MAb (Cortex Biochem). Horseradish peroxidase–conjugated secondary antibody with diaminobenzidine (DAB) as the chromogen (Biocare) was used for each chlamydial MAb. Positive controls were: (1) a CHsp60- and lipopolysaccharide-positive sample by IHC, and chlamydial DNA- or cDNA-positive sample by kPCR (see below); and (2) Cpn grown in U-937 macrophages and snap-frozen in OCT. Culture for Cpn was performed as described.13 Negative controls were: (1) a patient carotid plaque sample negative for Cpn by all tests; (2) excess IgG secondary antibody with chromogen DAB reacted against a Cpn-positive sample; and (3) mock-infected U-937 cells. Cpn antigens were similarly counted and normalized to cell number in 20 nonoverlapping fields of the same section as for IL-6.
Finally, the sections were stained using a CRP-specific MAb (R & D Systems) because a recent study found that CRP mediates biologic effects through Fc-gamma receptors on the aortic endothelium.14 Positive controls consisted of liver tissue prepared similarly to the carotid tissue. Negative controls were the liver tissue reacted with excess secondary antibody and mock-infected HeLa229 cells.
Quantitation of Plaque Cpn DNA and RNA
DNA and RNA were extracted from plaques using DNA tissue extraction and RNeasy Protect Kits (Qiagen), respectively, immediately after obtaining carotid tissue. For RNA, residual DNA was removed by treating the column with RNase-free DNase. cDNA was generated by reverse transcription using TaqMan Gold RT-PCR Kit (Applied Biosystems).15 The presence of cDNA was confirmed by spectrophotometry.
Primer Express (Applied Biosystems) was used to design primers (Table 1).15 Each primer pair was designed against all sequences from all public databases for the respective gene and subjected to BLAST (Basic Local Alignment Search Tool) to ensure specificity.
|
A plasmid for each of the 3 genes was constructed to create a standard curve for kPCR and kRT-PCR as described previously.15 PCR was performed9 using the primers (Table 1) to generate a PCR product for ligation into pCRII (TOPO TA cloning kit; Invitrogen). TOP10 Escherichia coli was transformed, and the plasmid was purified (GenElute HP; Sigma) and verified by sequencing. A standard formula was used to determine plasmid copy number per milliliter: y=Avogadro’s numberxconcentration (g/mL)/molecular weight (g)=molecules/mL.
kPCR or kRT-PCR using SYBR Green chemistry in an ABI7000 provided the copy number of DNA for each gene examined, as we have described previously.15 kRT-PCR was used to quantify number of viable Cpn genes. The following samples were run together in the same kPCR or kRT-PCR: triplicates of patient DNA or cDNA for each of the 3 primer pairs, 8 serial 2-fold dilutions of each plasmid (containing Cpn or ß-actin DNA insert) to generate standard curves for each gene, and 2 negative controls. Negative controls were: a no-template control (all reaction reagents except for cDNA); and no reverse transcription to test for residual DNA when cDNA was the template. Reactions consisted of 1X SYBR Green PCR master mix, 300 nmol/L of each primer, DNA, cDNA (patient sample), or DNA (plasmid), water to 50 µL, and thermocycling of 10 minutes at 95°C, and 40 cycles of 15 s at 95°C and 1 minute at 60°C.
Data were analyzed using Sequence Detection Software (ABI7000). DNA or cDNA copy number was determined using standard curves for the respective gene. Gene copy number was divided by ß-actin copy number so that the pathogen gene copy number could be expressed per eukaryotic cell as the pathogen burden. Melting curve analysis was used to verify that the primers detected the correct gene. kPCR or kRT-PCR products were run on 3% to 4% SeaPlaque agarose gels using ethidium bromide with molecular weight markers to verify the size product.
Expression of IL-6 by Quantitative Real-Time RT-PCR
To detect expression of IL-6, we performed kRT-PCR using the same patient cDNA (as above) and our previously published techniques.15 Experiments were performed in triplicate; data were analyzed as above except that quantitation for IL-6 gene expression was normalized against 18s rRNA gene expression for each kRT-PCR as described.15
Serum CRP and IL-6 Levels
CRP levels were initially determined using fixed-rate nephelometry (Quest Diagnostics)16 at a sensitivity of 0.4 mg/L. Levels below this were defined as not detectable. For all samples below this level, high-sensitivity CRP (hsCRP; Quest) was performed, which has a sensitivity level of 0.175 mg/L.
A commercial ELISA (Biosource) using biotin streptavidin horseradish peroxidase was used to measure IL-6 serum levels. Briefly, 8 standards (0 to 500 ng/L) and patient sera diluted 1:100 in triplicate were applied to a 96-well plate, incubated, and washed. An ELISA plate reader at 450 nm was used for determining substrate conversion. The end point dilution was OD >0.1 above the level of controls. Background was subtracted to normalize data; results were compared with the standard curve to compute concentrations and SEM for each of the 3 values for each sample.
Statistical Analysis
All continuous and categorical variables were not normally distributed, so we used nonparametric statistics for analyses. Univariate analysis was performed with Fisher exact test for dichotomous variables, Wilcoxon rank-sum test for comparison of categories of continuous variables, and Spearman rank correlation coefficient (R) for associations between continuous variables using Stata (Version 8.0).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Fifty-one endarterectomy samples were obtained from 49 patients (age mean±SD 72±9 years), 15 (29%) of whom were women. Treated carotid arteries were associated with symptoms attributable to stroke or transient ischemic attack in 14 patients (27%), a median of 56 days before surgery (range 1 to 1130 days); the remaining patients were asymptomatic, including both samples from the subjects with 2 samples. Five cases (10%) were reoperations. Vascular risk factors among patients were smoking (n=35), hypercholesterolemia (n=32), hypertension (n=32), and diabetes (n=10).
Two individuals had both carotids removed at separate times. Serum tests were done before each surgery and were correlated (CRP undetectable on both measures for subject A and 0.8/1.5 for B; IL-6 A 3.8/3.7; B 20.2/6.4). The plaque characteristics were also very similar, with subject A showing no expression of IL-6 or Cpn and B with IL-6 1.0/4.2 and kPCR 10.7/8.9.
PCR revealed Cpn in 20 plaques (39%), whereas kPCR detected infection in 22 (43%) and kRT-PCR detected viable organisms in 19 (37%). All plaques with viable organisms were also positive by kPCR and PCR (Table 2). Cpn was present in 28 (62%) of 45 plaques by IHC; 15 (83%) of 18 kRT-PCR positive plaques were also positive by IHC. Cpn plaque burden (copy number by kPCR) was directly associated with plaque IL-6 expression as measured by kRT-PCR of IL-6 mRNA (Tables 2 and 3
; nonparametric Spearman R=0.55; P<0.0001; Figure 1A). Although Cpn was not associated with plaque IL-6 by IHC (Table 2), Cpn plaque burden was correlated with degree of IL-6 IHC staining (Table 3).
|
|
|
IL-6 colocalized with Cpn antigen staining by IHC, primarily in the endothelium (Figure 2D); the carotid plaque revealed Cpn (arrows; brown staining with DAB) and colocalization with IL-6 (arrowheads; staining with Fast Red) in the same cells in the endothelium. Figure 2A shows the carotid section from a patient with atherosclerosis; Cpn was stained with CHsp60-specific MAb, and the nuclear counter stain was hematoxylin. Figure 2B shows a positive control for Cpn, where the organism was cultured in U-937 macrophages, pelleted, snap-frozen, sectioned, and stained with CHsp60-specific MAb (arrows). As a negative control, we used a carotid section with no evidence for Cpn by IHC staining (kPCR and kRT-PCR; Figure 2C).
|
We found evidence for CRP staining in injured vascular endothelial tissue. However, there were no differences in overall staining among the sections and therefore no statistically significant difference between those sections with or without Cpn by IHC, kPCR, or kRT-PCR, or between those sections with or without upregulation of IL-6 by kRT-PCR or IHC for CRP.
Serum CRP levels before endarterectomy ranged from undetectable to 86 mg/L, with a median below the detection threshold. CRP levels that were undetectable remained so on repeat testing with the hsCRP test. IL-6 serum levels were measured before endarterectomy and ranged from 3.1 to 333.2 pg/µL (median 6.6 pg/µL). CRP and IL-6 serum levels were correlated (R=0.77; P<0.0001).
Serum CRP levels were significantly associated with Cpn infection by all tests and with Cpn burden (Tables 3 and 4; R=0.56; P<0.0001; Figure 1B). IL-6 serum levels were associated with Cpn burden only by kPCR. Serum levels of CRP and IL-6 were strongly associated with plaque IL-6 expression by kRT-PCR and IHC.
|
IL-6 plaque expression was associated with serum levels of CRP (R=0.80; P<0.0001; Figure 1C) and serum IL-6 (R=0.56; P<0.0001; Figure 1D). Similarly, IL-6 plaque levels by IHC were associated with serum levels of CRP and IL-6 (Table 3).
Symptomatic presentation was not associated with any serum or plaque measure. Serum inflammatory markers and plaque characteristics were similar for both tests done on the subjects with 2 specimens; results were nearly identical when only the first measure from each was used in subsequent analyses.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We previously reported an association between Cpn in carotid plaques and serum levels of CRP.9 Our current study confirms our findings by demonstrating that serum CRP levels are associated with Cpn burden and quantified by kPCR and semiquantitative IHC. Cpn burden in carotid plaques was also associated with plaque IL-6 expression. Furthermore, cells with Cpn antigens tended to colocalize with IL-6. Higher IL-6 plaque expression was associated with higher serum CRP and, to a lesser degree, with higher serum IL-6 levels.
Cpn is a potent inducer of IL-6.17 In vitro infection of human vascular smooth muscle cells with Cpn upregulates IL-6 expression and basic fibroblast growth factor, suggesting a mechanism of fibrous plaque formation in arterial disease.18 Cpn-infected cells secret increased quantities of IL-6 in a time-dependent fashion 48 hours after inoculation, which is proportional to the Cpn burden. Furthermore, in vitro inhibition of Cpn protein synthesis by chloramphenicol prevents upregulation of IL-6 expression.19 These findings are consistent with our study in that Cpn burden, after controlling for the number of eukaryotic cells, was significantly associated with plaque IL-6 expression. Other inflammatory cytokines released by Cpn-infected cells such as IL-1 could also contribute to CRP production.20 Consequently, Cpn burden may directly influence the degree of plaque inflammation. Yet, it is important to note that the plaques in this study were of a high grade, which may promote an incubator effect for Cpn and a greater degree of inflammation that is not representative of atherosclerosis in general. Further, the nonspecific presence of CRP in injured vasculature would be expected in high-grade plaques. Thus, although we found no association of Cpn with symptomatic vascular disease and would not expect to because most patients with atherosclerosis do not have symptoms from the disease, the data suggest that Cpn is associated with inflammation and atherogenesis via arterial tissue and systemic markers of inflammation.
Increasing evidence suggests that IL-6 is important in atherosclerotic progression. IL-6 is expressed by endothelium and macrophages,21 representing foam cells, which are an early marker of atherosclerosis. IL-6 also has procoagulant effects on platelets, activates monocytes in vascular tissue, increases endothelial release of adhesion molecules, inhibits lipoprotein lipase, and stimulates lipolysis, all of which contribute to the development of vascular disease.22 We found that plaque expression of IL-6 was associated with serum levels of IL-6. Serum levels of IL-6 have been associated with cardiovascular disease risk. In the Physicians’ Health Study, those with IL-6 levels in the highest quartile were at a 2.3-fold greater risk of future cardiovascular events compared with those in the lowest quartile.6 CRP levels were strongly correlated with IL-6, but the association between IL-6 and cardiovascular disease risk persisted after adjustment for CRP levels.
IL-6 is the primary determinant of CRP release from the liver.23 Consequently, it is not surprising that we found a strong association between serum CRP and plaque IL-6 expression and serum IL-6 levels. Because plaque IL-6 expression is associated with serum IL-6, it is plausible that IL-6 stimulates CRP production, which indirectly reflects localized plaque inflammation. The high degree of IL-6 staining in plaques suggests that plaques may be the source of elevated serum IL-6. Although CRP levels increase via several mechanisms, chronic vascular wall infection and inflammation may be an important stimulus, with IL-6 acting as the primary messenger. Thus, Cpn may induce plaque production of IL-6, which could subsequently cause elevation in serum CRP and IL-6.
We found evidence for Cpn in 37% of carotid plaques. Others have reported Cpn in 0% to 100% of atherosclerotic plaques. In a review of 43 studies with 1852 specimens, an average of 46% had evidence for Cpn infection.24 This range likely reflects the variety of techniques used to identify Cpn and the samples studied. However, contamination or false positives, especially with PCR, may be an issue.25 The consistency of our findings with a high correlation of PCR, kPCR (DNA), kRT-PCR (RNA), and semiquantitative IHC results for Cpn in the plaques (P<0.0001) and independent performance of each test are inconsistent with contamination or false positives. Furthermore, the association of plaque Cpn with serum IL-6 and CRP cannot be explained by contamination because blood and tissue samples were handled completely separately.
Cpn may still be an innocent bystander in plaques because infected monocytes are recruited to these sites. CRP and plaque inflammation, indicated by plaque IL-6 expression, may correlate with upstream factors associated with risk or overall severity of atherosclerosis, whereas Cpn burden may simply be determined by the degree of cellular infiltration into the plaques. Arguing against this, the burden of Cpn was determined based on number of Cpn normalized against eukaryotic cells. Furthermore, within plaque sections, expression of IL-6 tended to cluster around cells with Cpn.
Trials of antibiotic treatment for Cpn in coronary artery disease have shown variable results, with no overall benefit.11,12,26 These studies failed either because Cpn is not a causative factor in atherosclerosis or the treatment was inadequate. Our study found that Cpn was associated with inflammation via inflammatory markers, which likely play a role in disease development and progression. Thus, our data are not inconsistent with previous findings. Treatment has reduced serum levels of CRP in some studies, but information about the reduction in plaque inflammation or Cpn eradication is not available and would be important in establishing a definitive role for Cpn in atherosclerosis.
|
Acknowledgments |
|---|
This study was funded by Pacific Vascular Research Foundation and the National Institutes of Health (NS02042 to S.C.J. and AI39499 to D.D.). We thank Catherine McDonough for excellent technical assistance.
Received May 25, 2005; accepted September 26, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999; 340: 115–126.
2. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology. 1991; 23: 118–124.[Medline] [Order article via Infotrieve]
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
4. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med. 2000; 343: 1179–1182.
5. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999; 106: 506–512.[CrossRef][Medline] [Order article via Infotrieve]
6. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101: 1767–1772.
7. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc. 2001; 286: 2107–2113.
8. Baumann H, Morella KK, Jahreis GP, Marinkovic S. Distinct regulation of the interleukin-1 and interleukin-6 response elements of the rat haptoglobin gene in rat and human hepatoma cells. Mol Cell Biol. 1990; 10: 5967–5976.
9. Johnston SC, Messina LM, Browner WS, Lawton MT, Morris C, Dean D. C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke. 2001; 32: 2748–2752.
10. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993; 13: 1501–1504.
11. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005; 352: 1646–1654.
12. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C. Azithromycin for the secondary prevention of coronary events. N Engl J Med. 2005; 352: 1637–1645.
13. Dean D, Neumayr L, Kelly DM, Ballas SK, Kleman K, Robertson S, Iyer RV, Ware RE, Koshy M, Rackoff WR, Pegelow CH, Waldron P, Benjamin L, Vichinsky E. Chlamydia pneumoniae and acute chest syndrome in patients with sickle cell disease. J Pediatr Hematol Oncol. 2003; 25: 46–55.[CrossRef][Medline] [Order article via Infotrieve]
14. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol. 2005; 25: 1359–1363.
15. Gomes JP, Hsia RC, Mead S, Borrego MJ, Dean D. Immunoreactivity and differential developmental expression of known and putative Chlamydia trachomatis membrane proteins for biologically variant serovars representing distinct disease groups. Microbes Infect. 2005; 7: 410–420.[CrossRef][Medline] [Order article via Infotrieve]
16. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol. 1990; 65: 168–172.[CrossRef][Medline] [Order article via Infotrieve]
17. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996; 21: 215–221.[CrossRef][Medline] [Order article via Infotrieve]
18. Rodel J, Woytas M, Groh A, Schmidt KH, Hartmann M, Lehmann M, Straube E. Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect. Immun. 2000; 68: 3635–3641.
19. Kutlin A, Roblin PM, Hammerschlag MR. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 2002; 46: 409–412.
20. Rupp J, Kothe H, Mueller A, Maass M, Dalhoff K. Imbalanced secretion of IL-1beta and IL-1RA in Chlamydia pneumoniae-infected mononuclear cells from COPD patients. Eur Respir J. 2003; 22: 274–279.
21. Kofler S, Nickel T, Weis M The role of cytokines in cardiovascular diseases. Focus on endothelial response to inflammation. Clin Sci (Lond). 2004.
22. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148: 209–214.[CrossRef][Medline] [Order article via Infotrieve]
23. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992; 35: 982–984.[Medline] [Order article via Infotrieve]
24. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. J Am Med Assoc. 2002; 288: 2724–2731.
25. Apfalter P, Hammerschlag MR, Boman J. Reliability of nested PCR for the detection of Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke. 2003; 34: e73–e75.
26. Etminan M, Carleton B, Delaney JA, Padwal R. Macrolide therapy for Chlamydia pneumoniae in the secondary prevention of coronary artery disease: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2004; 24: 338–343.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  S. Bunk, I. Susnea, J. Rupp, J. T. Summersgill, M. Maass, W. Stegmann, A. Schrattenholz, A. Wendel, M. Przybylski, and C. Hermann Immunoproteomic Identification and Serological Responses to Novel Chlamydia pneumoniae Antigens That Are Associated with Persistent C. pneumoniae Infections J. Immunol., April 15, 2008; 180(8): 5490 - 5498. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||